Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer

• Published in: Gynecologic oncology 2014-03, Vol.132 (3), p.703-708
• Main Authors: Nishio, Shin, Ushijima, Kimio, Yamaguchi, Tomohiko, Sasajima, Yuko, Tsuda, Hitoshi, Kasamatsu, Takahiro, Kage, Masayoshi, Ono, Mayumi, Kuwano, Michihiko, Kamura, Toshiharu
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers, Tumor - biosynthesis; Cervical cancer; Disease-Free Survival; EGFR; Female; Hematology, Oncology and Palliative Medicine; Humans; Hysterectomy; Immunohistochemistry; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Staging; Obstetrics and Gynecology; Prognosis; Receptor, Epidermal Growth Factor - biosynthesis; Receptor, ErbB-2 - biosynthesis; Uterine Cervical Neoplasms - metabolism; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Y-Box-Binding Protein 1 - biosynthesis; YB-1; Young Adult
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2014.01.045

Abstract Objective Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many studies indicate that YB-1 is strongly expressed in tumor cells and is considered a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer. Clinical trials of EGFR family-base therapy are currently being initiated in cervical cancer. Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. However, the clinical significance of nuclear YB-1 expression in different settings, the correlation with EGFR, and the prognostic implications of YB-1 expression in cervical cancer remain elusive. Patients and methods Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 patients with cervical cancer who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival, EGFR expression, and human epidermal growth factor receptor 2 (HER2) expression were investigated. Results Nuclear YB-1 expression was found in 41 (20.2%) of 204 cases of cervical cancer and correlated with disease stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with EGFR expression ( P = 0.0114) as well as HER2 expression ( P = 0.0053). Kaplan–Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor progression-free survival ( P = 0.0033) and overall survival ( P = 0.0003), respectively. Conclusion Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in cervical cancer.